Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis

Arquivos de Gastroenterologia

Volumn 42, Issue 4, 2005, Pages 256-262

  Alvarez, Roberto Fiolic ^a   De Mattos, Angelo Alves ^a,e   Corrêa, Esther Buzaglo Dantas ^b   Cotrim, Helma Pinchemel ^c   Nascimento, Tereza Virginia S B ^d  

^a Federal School of Medical Sciences of Porto Alegre   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^d University of Sergipe School of Medicine   (Brazil)

^e NONE   (Brazil)

Author keywords

Ascites; Liver cirrhosis; Norfloxacin; Peritonitis; Trimethoprim sulfamethoxazole combination

Indexed keywords

COTRIMOXAZOLE; NORFLOXACIN;

ADULT; ARTICLE; ASCITES; ASCITES FLUID; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; CONCENTRATION (PARAMETERS); DRUG EFFICACY; DRUG FATALITY; EPIGASTRIC PAIN; FEMALE; HUMAN; INFECTION; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT; RASH; RESPIRATORY TRACT INFECTION; SEPSIS; SKIN INFECTION; STATISTICAL ANALYSIS; URINARY TRACT INFECTION;

EID: 32544448831     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032005000400012     Document Type: Article

References (46)

1. Almdal TP, Skinhoj P. Spontaneous bacterial peritonitis in cirrhosis: incidence, diagnosis, and prognosis. Scand J Gastroenterol 1987;22:295-300.
2. Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, Coll S, Oliver MT. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133-8.
3. Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998;59:54-7.
4. Bernard B, Grangé JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-61.
5. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993;18:353-8.
6. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998;26:1066-70.
7. Conn HO, Fessel JM. Spontaneous bacterial peritonitis in cirrhosis variations on a theme. Medicine 1971;50:161-97.
8. Coral GP, Mattos AA, Damo DF, Viégas AC. Prevalência e prognóstico da peritonite bacteriana espontânea. Arq Gastroenterol 2002;39:158-62.
9. Coral GP, Mattos AA. Renal impairment after spontaneous bacterial peritonitis: incidence and prognosis. Can J Gastroenterol 2003;17:187-90.
10. Curry N, McCallum RW, Guth PH. Spontaneous peritonitis in cirrhotic ascites. A decade of experience. Am J Dig Dis 1974;19:685-92.
11. Deshmukh SR, Nagoba BS, Wadher BJ, Tumane P. Norfloxacin induced resistance to fluoroquinolones and structurally unrelated antimicrobial agents in coagulase negative staphylococci. Indian J Med Res 1997;106:461-4.
12. Dupeyron C, Manganey N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfioxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994;38:340-4.
13. Fernandez J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodes J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8.
14. Figueiredo FA, Coelho HS, Soares JA. Peritonite bacteriana espontânea na cirrose hepática: prevalência, fatores preditivos e prognóstico. Rev Assoc Med Bras 1999;45:128-36.
15. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Franitorra A, Rimola A, Gassul MA, Arroyo Y, Rodes J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course predictive factors and prognosis. Hepatology 1994;20:1495-501.
16. Ginès P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forne M, Miranda MC, Llach J, Salmeron JN. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-bind, placebo-controlled trial. Hepatology 1990;12:716-24.
17. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, Blanc P, Richardet JP, Vinel JP, Delisle F, Fescher D, Flahault A, Amiot X. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998;29:430-6.
18. Guarner C, Soriano G. Spontaneous bacterial peritonitis. Semin Liver Dis 1997;17:203-17.
19. Guarner C, Solá R, Soriano G, Andreu M, Novella MT, Vila MC, Sabat M, Coll S, Ortiz J, Gomez C, Balanzo J. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999;117:414-9.
20. Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997;113:1289-94.
21. Llovet JM, Planas R, Morillas R, Quer JC, Gabré E, Boix J, Humbert P, Guilera M, Domenech E, Bestran X. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol 1993;88:388-92.
22. Llovet JM, Bartoli R, Planas R, Cabré E, Jimenez M, Urban A, Ojanguren I, Arnal J, Gassull MA. Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis. Gut 1994;35:1648-52.
23. Mattos AA, Pereira-Lima J. Estudo do líquido de ascite. Rev AMRlGS 1983;27:294-301.
24. Mattos AA. Papel do nível de proteínas no líquido de ascite na predisposição à peritonite bacteriana espontânea e suas variantes. GED Gastroenterol Endosc Dig 1993;12:73-9.
25. Mattos AA, Pereira-Lima J, Both CT. O papel do gradiente de albumina soro-ascite na elucidação diagnóstica das ascites. GED Gastroenterol Endosc Dig 1993;12:27-31.
26. Mattos M, Machado SB, Balle VR, Dominguez W. Sobrevida de pacientes cirróticos com ascite. GED Gastroenterol Endosc Dig 1998;17:17-21.
27. Mattos AA, Coral GP, Menti E, Valiatti F, Kramer C. Bacterial infection in cirrhotic patients. Arq Gastroenterol 2003;40:11-5.
28. Navasa M, Rimola A, Rodés J. Bacterial infections in liver disease. Semin Liver Dis 1997;17:323-33.
29. Navasa M, Follo A, Filella X, Jimenez W, Francitorra A, Planas R, Rimola A, Arroyo V, Rodes J. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-32.
30. Navasa M, Fernández J, Arroyo V, Rodés J. Prophylaxis of bacterial infections in cirrhosis. In: Arroyo V, Bosch J, Bruguera M, Rodés J, Tapias JMS, editors. Treatment of liver disease. Barcelona: Masson AS; 1999. p.103-8.
31. Navasa M, Fernandez J, Rodes J. Prophylaxis of spontaneous bacterial peritonitis. The problem of spontaneous bacterial peritonitis by quinolone-resistant bacteria. In: Arroyo V, Bosch J, Bruix J, Ginés P, Navasa M, editors. Therapy in hepatology. Barcelona: Ars Medica; 2001. p.65-71.
32. Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, Sabat M, Vila MC, Guarner C, Vilardell F. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25:532-6.
33. Ortiz J, Vila M C, Soriano G, Minãna J, Gana J, Mirelis B, Novella MT, Coll S, Sabat M, Andreu M, Sola R, Guarner C. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999;29:1064-9.
34. Rimola A, Garcia-Tsao G, Navasa M, Piddocj LJ, Plantas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000;32:142-53.
35. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, Fratte S, Bohn B, Kitmacher P, Stahl JP, Zarski JP. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171-4.
36. Rosa H, Silvério AO, Perini RF, Arruda CB. Bacterial infection in cirrhotic patients and its relationship with alcohol. Am J Gastroenterol 2000;95:1290-3.
37. Runyon, BA. Low-protein concentration ascitic fluid predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986;91:1343-6.
38. Runyon BA. Spontaneous bacterial peritonitis: an explosion of information. Hepatology 1988;8:171-5.
39. Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988;95:1351-5.
40. Runyon BA, Practice Guidelines Committee, American Association for the Study of liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841-56.
41. Singh N, Gayowski I, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995;122:595-8.
42. Soriano G, Guarner C, Teixido N, Such J, Barrios LI, Enriquez J, Vilardell F. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991;100:477-81.
43. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
44. Terg R, Llano K, Cobas SM, Brotto C, Barrios A, Levi D, Wasen W, Bartelline MA. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short and long-term administration, with daily and weekly dosages. J Hepatol 1998;29:437-42.
45. Tito L, Rimola A, Guiness P, Llach J, Arroyo V, Rodes J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27-31.
46. Toledo C, Salmeron JM, Rimola A, Navasa M, Arroyo V, Llach J, Chines A, Gines P, Rodes J. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-7.